Keystone Financial Services Purchases 892 Shares of Sanofi (NASDAQ:SNY)

Keystone Financial Services raised its position in shares of Sanofi (NASDAQ:SNY) by 7.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,605 shares of the company’s stock after acquiring an additional 892 shares during the period. Keystone Financial Services’ holdings in Sanofi were worth $784,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in SNY. POM Investment Strategies LLC bought a new position in Sanofi in the second quarter worth about $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi in the 3rd quarter worth approximately $29,000. Concord Wealth Partners boosted its position in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp purchased a new stake in Sanofi in the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC lifted its position in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY stock opened at $50.62 on Tuesday. The company has a market capitalization of $128.46 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 1.31 and a beta of 0.61. The firm has a fifty day simple moving average of $55.38 and a 200-day simple moving average of $52.24. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $45.13 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the prior year, the firm posted $2.55 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Sanofi will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research reports. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.